Abstract: Methods and compositions are provided for identifying novel conformers of proteins not known to exist as different conformers. By using chimeric genes replacing a native signal sequence with a different signal sequence resulting in the production of a conformer, one can compare the native protein with the product of the chimeric gene. Where the conformations are different, the different protein may be used for production of antibodies, elucidation of mechanisms associated with the native and different conformer protein, assays for the presence of the different conformer in physiological samples, identification of compounds specifically binding to the conformer, particularly drugs, etc. Where the formation of the conformer is associated with a diseased state, the conformer may be used in screens to identify compounds as drug candidates.
Type:
Grant
Filed:
December 15, 2000
Date of Patent:
November 23, 2004
Assignee:
Regents of the University of California
Inventors:
Vishwanath R. Lingappa, D. Thomas Rutkowski, Ramanujan S. Hegde
Abstract: Methods and compositions are provided comprising ingestibles and a thermochromic composition which is informative as to the temperature history of the ingestible, either prior or contemporaneous with use. Various solid or liquid ingestible compositions are provided for determining storage temperature, temperature of the user, temperature of the ingestible, particularly comestibles, and the like. Of particular interest are polydiacetylene polymers which may be formulated to provide compositions having transition temperature over a broad temperature range.
Abstract: A device is provided for the filter and collection of one or more material. The device incorporates a manifold with an inlet conduit and an outlet conduit, with an adjustable control handle on the top of the manifold and a baffle plate in the inside of the manifold. The manifold is sealed to the top opening of a collection chamber. During procedures which require withdrawal of material not to be collected, the control handle and baffle plate are adjusted to a pass-through mode which connects a internal adjustable conduit, which transverses through the baffle plate, with the lumen of the inlet and outlet conduits to form a continuous lumen with which to withdraw material not to be collected through. During procedures which require the withdrawal of material to be collected, the control handle and baffle plate are adjusted to a solids mode which orients the baffle plate to face both the lumen of the inlet and outlet conduits.
Abstract: A cell-free method for translation and assembly of retroviral, particularly HIV, capsid and capsid intermediates is disclosed. Also disclosed are novel HIV capsid assembly intermediates and novel host proteins which bind to such assembly intermediates. The invention also includes a screening method for compounds that alter retrovirus capsid assembly, and a method of treating HIV using compounds which inhibit the HIV capsid assembly pathway.
Type:
Grant
Filed:
February 6, 1998
Date of Patent:
July 15, 2003
Assignee:
The Regents of the University of California
Inventors:
Jaisri R. Lingappa, Vishwanath R. Lingappa
Abstract: Methods and compositions for treating diabetes mellitus in a patient in need thereof are provided. The methods include administering to a patient a composition providing a gastrin/CCK receptor ligand, e.g., a gastrin, and/or an epidermal growth factor (EGF) receptor ligand, e.g., TGF-&agr;, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g., a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g., a TGF-&agr; gene. The methods also include transplanting into a patient cultured pancreatic islets in which mature insulin-secreting beta cells are proliferated by exposure to a gastrin/CCK receptor ligand and an EGF receptor ligand.
Type:
Grant
Filed:
January 29, 1999
Date of Patent:
May 6, 2003
Assignees:
Waratah Pharmaceuticals, Inc., The General Hospital Corporation
Inventors:
Indu Parikh, Anne Lane, Ronald V. Nardi, Stephen J. Brand
Abstract: The ethyl ester of derivatives of benzoyl ecgonine are provided having a linking group at the para position of the benzoyl group. The derivatives are used to bond to immunogenic polypeptides for production of antisera and monoclonal antibodies. The antisera and antibodies find use in assays, for treatment of cocaine overdose and detoxification.
Type:
Grant
Filed:
January 4, 2000
Date of Patent:
April 1, 2003
Assignee:
DrugAbuse Sciences, Inc.
Inventors:
Jean-Michel Scherrmann, Philippe Pouletty, Herve Galons
Abstract: Substituted phenylalanines are provided comprising an hydantoin, urea or 2-hydroxyl, 2-methylpropionyl group, dimers thereof and alkyl, polyfluoroamido and haloarylamino derivatives thereof, as well as radiolabeled derivatives thereof. The compounds bind specifically to the androgen receptor and find use in indications associated with the androgen receptor, such as cell hyperplasia dependent on androgens, hirsutism, acne and androgenetic alopecia.
Type:
Grant
Filed:
February 11, 2000
Date of Patent:
October 29, 2002
Assignee:
Biophysica, Inc.
Inventors:
Milos Sovak, Allen L. Seligson, James Gordon Douglas, III, Brian Campion, Jason W. Brown
Abstract: Diyne monomers are used as photochromic agents in devices or formulations. The devices and formulations may be applied to body parts for semi-pemanent attachment at various sites to allow for detection of levels of ultraviolet radiation. Clear films may be placed on eyeglass lenses to detect UV radiation occurring between the lens and the eye.
Abstract: ADMA is determined in a physiological sample by first removing interfering components: proteins by precipitation; and amines and citrulline, by means of a cation exchange column, followed by enzymatic hydrolysis of the ADMA to citrulline with DDAH. The citrulline is then determined spectrophotometrically.
Type:
Grant
Filed:
February 1, 2000
Date of Patent:
March 19, 2002
Assignees:
Cooke Pharma, Panorama Research, Inc.
Inventors:
Robert F. Balint, Mitchell Wayne Mutz, John P. Cooke
Abstract: Novel methods are provided whereby encoding sequences preferentially directing gene expression in ovary tissue, particularly in very early fruit development, are utilized to express genes encoding isopentenyl transferase in cotton ovule tissue. The methods permit the modification of the characteristics of boll set in cotton plants and provide a mechanism for altering fiber quality characteristics including fiber dimension and strength.
Abstract: Recombinant genetic information (DNA or RNA), comprising a Chicken Anemia Virus (CAV)-specific nucleotide sequence and the use thereof for diagnostics, vaccination or protein production. Recombinant CAV protein and the use thereof for diagnostics, vaccination or production of CAV-specific antibodies. The use of CAV-specific antibodies thus obtained.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
November 20, 2001
Assignee:
Leadd B.V.
Inventors:
Matheus H. M. Noteborn, Gerben F. de Boer
Abstract: An injectable slow-release naltrexone formulation is provided comprising naltrexone in a poly(D,L-lactide) matrix with a small amount of residual ethyl acetate. Upon intramuscular injection of the composition, naltrexone is released in a controlled manner over an extended period of time. The composition finds use in the treatment of heroin addicts and alcoholics to reduce consumption of the abused substances.
Type:
Grant
Filed:
April 7, 2000
Date of Patent:
October 23, 2001
Assignee:
Southern Research Institute
Inventors:
Thomas R. Tice, Jay K. Staas, Teresa M. Ferrell
Abstract: Methods and compositions are provided for the modification of polysaccharide structures using polysaccharidase binding or catalytic domains either alone or in tandem to modify the structure of polysaccharides. These methods and compositions are exemplified by the use of cellulase binding and catalytic domains to polish cotton, and to alter dying characteristics, texture and porosity of cellulose fibers.
Type:
Grant
Filed:
October 13, 1998
Date of Patent:
October 9, 2001
Assignee:
University of British Columbia
Inventors:
Neil R. Gilkes, Douglas G. Kilburn, Robert C. Miller, Jr., Anthony Warren
Abstract: A method for treating diabetes mellitus by administering composition providing a gastrin/CCK receptor ligand, e.g. a gastrin, and an EGF receptor ligand, e.g. TGF&agr;, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g. a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g. a TGF&agr; gene.
Type:
Grant
Filed:
July 30, 1998
Date of Patent:
September 11, 2001
Assignees:
Waratah Pharmaceuticals, Inc., The General Hospital Corporation
Abstract: Regulatory regions from genes expressed during a particular developmental stage or in a specific tissue are identified employing cDNA screening. The resulting regulatory regions are manipulated for use with foreign sequences for introduction into plant cells to provide transformed plants having phenotypic property which can be modulated. The invention is exemplified with light, seed and a fruit-specific promoters.
Abstract: Novel DNA constructs are provided which may be used as molecular probes or inserted into a plant host to provide for modification of transcription of a DNA sequence of interest in ovary tissue, particularly in very early fruit development. The DNA constructs comprise a transcriptional initiation regulatory region associated with gene expression in ovary tissue from immediately prior to anthesis through flower senescence.
Abstract: Circular double-stranded replication intermediates were identified in low-molecular-weight DNA of cells of the avian leukemia virus-induced lymphoblastoid cell line 1104-X-5 infected with chicken anemia virus (CAV). To characterize the genome of CAV, we cloned linearized CAV DNA into the vector pIC20H. Transfection of the circularized cloned insert into chicken cell lines caused a cytopathogenic effect, which was arrested when a chicken serum with neutralizing antibodies directed against CAV was added. The 2,319-bp cloned CAV DNA contained all the genetic information needed for the complete replication cycle of CAV. The CAV genome probably contains only one promoter region and only one poly(A) addition signal. Southern blot analysis using oligomers derived from the CAV DNA sequence showed that infected cells contained double- and single-stranded CAV DNAs, whereas purified virus contained only the minus strand.
Type:
Grant
Filed:
August 13, 1997
Date of Patent:
May 29, 2001
Assignee:
Leadd, bv
Inventors:
Mathews H. M. Noteborn, Gerden F. De Boer
Abstract: Novel DNA constructs are provided which may be used as molecular probes or inserted into a plant host to provide for modification of transcription of a DNA sequence of interest in ovary tissue, particularly in very early fruit development. The DNA constructs comprise a transcriptional initiation regulatory region associated with gene expression in ovary tissue from immediately prior to anthesis through flower senescence.
Abstract: Methods and compositions are offered for reducing nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia), where intradermal delivery of lidocaine is maintained for a predetermined period of time. The lidocaine appears to specifically affect the damaged nerve fibers, while leaving the undamaged and normal nerve fibers with retention of response to other stimuli. Lidocaine formulations are provided which allow for the necessary dosage of the lidocaine in the dermis during the period of treatment. The formulation may be covered with an occlusive or non-occlusive dressing, which protects the lidocaine formulation from mechanical removal and enhances the transport of the lidocaine into the dermis. Long term relief is realized after maintenance of the administration of lidocaine has been terminated.
Abstract: Sucrose phosphate synthase (SPS), its process for preparation, its cDNA, and utilization of cDNA to modify the expression of SPS in the plant cells are provided.
Type:
Grant
Filed:
September 9, 1999
Date of Patent:
February 24, 2004
Assignees:
Calgene, LLC., Roussel Uclaf
Inventors:
Charles Van Assche, Danielle Lando, Jean Michel Bruneau, Toni Alois Voelker, Monica Gervais